Skip to main content
. 2021 Feb 1;39(4):1028–1035. doi: 10.1007/s10637-020-01054-6

Table 3.

Best overall response in patients receiving BI 836826 plus GemOx

BI 836826 dose
Patients with response, n (%) 25 mg
(n = 5)
50 mg
(n = 8)
100 mg
(n = 8)
Total
(n = 21)
Complete remission 1 (20.0) 0 1 (12.5) 2 (9.5)
Partial remission 2 (40.0) 3 (37.5) 1 (12.5) 6 (28.6)
Stable disease 2 (40.0) 1 (12.5) 3 (37.5) 6 (28.6)
Progressive disease 0 2 (25.0) 1 (12.5) 3 (14.3)
Missing 0 2 (25.0) 2 (25.0) 4 (19.0)

GemOx gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2